发明名称 USE OF FGFR1 EXTRA CELLULAR DOMAIN PROTEINS TO TREAT CANCERS CHARACTERIZED BY LIGAND-DEPENDENT ACTIVATING MUTATIONS IN FGFR2
摘要 The present invention relates to the use of Fibroblast Growth Factor Receptor I (FGFR1) extracellular domain (ECD) polypeptides for treatment of cancers characterized by ligand dependent activating mutations in Fibroblast Growth Factor Receptor 2 (FGFR2). For example, the present invention relates to the treatment of endometrial cancers and other cancers wherein tumor cells express FGFR2 mutants in the IgII-IgIII hinge region or IgIII domain of the protein, such as at amino acid positions 252 and/or 253.
申请公布号 US2012251538(A1) 申请公布日期 2012.10.04
申请号 US201013509068 申请日期 2010.11.12
申请人 HARDING THOMAS;KAVANAUGH MICHAEL W.;FIVE PRIME PHARMACEUTIALS, INC. 发明人 HARDING THOMAS;KAVANAUGH MICHAEL W.
分类号 A61K38/17;A61K39/395;A61P35/00 主分类号 A61K38/17
代理机构 代理人
主权项
地址